Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oncocyte Corp (OCX) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Oncocyte Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 1642380.
Total stock buying since 2018: $91,141,362.
Total stock sales since 2018: $16,437,401.
Total stock option exercises since 2018: $167,498.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 6,345,969 | $7,714,192 | 0 | $0 | 0 | $0 |
| 2024 | 3,826,297 | $5,722,967 | 0 | $0 | 0 | $0 |
| 2023 | 27,520,638 | $4,257,649 | 0 | $0 | 0 | $0 |
| 2022 | 12,712,459 | $12,206,380 | 107,514 | $112,527 | 335,000 | $0 |
| 2021 | 2,071,280 | $3,902,700 | 0 | $0 | 85,000 | $0 |
| 2020 | 2,546,682 | $45,529,468 | 2,426,790 | $5,184,874 | 145,000 | $167,498 |
| 2019 | 4,779,804 | $6,808,006 | 6,250,000 | $11,140,000 | 0 | $0 |
| 2018 | 4,105,492 | $5,000,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-02 | 6,340,881 | $7,703,967 | 0 | $0 | 0 | $0 |
| 2025-01 | 5,088 | $10,225 | 0 | $0 | 0 | $0 |
| 2024-12 | 20,000 | $45,800 | 0 | $0 | 0 | $0 |
| 2024-10 | 1,349,009 | $2,038,808 | 0 | $0 | 0 | $0 |
| 2024-04 | 2,457,288 | $3,638,359 | 0 | $0 | 0 | $0 |
| 2023-06 | 30,000 | $6,450 | 0 | $0 | 0 | $0 |
| 2023-04 | 27,490,638 | $4,251,199 | 0 | $0 | 0 | $0 |
| 2022-12 | 350,000 | $119,874 | 0 | $0 | 250,000 | $0 |
| 2022-08 | 280,500 | $266,345 | 0 | $0 | 0 | $0 |
| 2022-06 | 0 | $0 | 99,386 | $103,262 | 60,000 | $0 |
| 2022-05 | 0 | $0 | 8,128 | $9,265 | 25,000 | $0 |
| 2022-04 | 11,935,459 | $11,638,536 | 0 | $0 | 0 | $0 |
| 2022-03 | 146,500 | $181,625 | 0 | $0 | 0 | $0 |
| 2021-07 | 0 | $0 | 0 | $0 | 65,000 | $0 |
| 2021-04 | 0 | $0 | 0 | $0 | 20,000 | $0 |
| 2021-03 | 11,000 | $52,701 | 0 | $0 | 0 | $0 |
| 2021-02 | 600,000 | $1,350,000 | 0 | $0 | 0 | $0 |
| 2021-01 | 1,460,280 | $2,499,999 | 0 | $0 | 0 | $0 |
| 2020-12 | 0 | $0 | 43,700 | $46,932 | 125,000 | $167,498 |
| 2020-08 | 60,000 | $80,265 | 0 | $0 | 0 | $0 |
| 2020-04 | 1,050,000 | $1,191,750 | 0 | $0 | 0 | $0 |
| 2020-03 | 45,216 | $42,757,453 | 0 | $0 | 20,000 | $0 |
| 2020-01 | 1,391,466 | $1,500,000 | 2,383,090 | $5,137,942 | 0 | $0 |
| 2019-11 | 1,176,471 | $1,000,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-07 | James Andrea S. (Chief Financial Officer) | Buy | 97,561 | 2.05 | 200,000 |
| 2025-02-07 | Smith Patrick W | Buy | 1,077,600 | 2.05 | 2,209,080 |
| 2025-02-06 | Bradsher Neal C | Buy | 5,165,695 | 1.02 | 5,294,837 |
| 2025-02-04 | Smith Patrick W | Buy | 25 | 2.02 | 50 |
| 2025-01-31 | Smith Patrick W | Buy | 890 | 2.01 | 1,788 |
| 2025-01-30 | Smith Patrick W | Buy | 318 | 2.01 | 639 |
| 2025-01-29 | Smith Patrick W | Buy | 3,880 | 2.01 | 7,798 |
| 2024-12-05 | James Andrea S. (Chief Financial Officer) | Buy | 20,000 | 2.29 | 45,800 |
| 2024-10-02 | James Andrea S. (Chief Financial Officer) | Buy | 33,670 | 2.97 | 99,999 |
| 2024-10-02 | Bradsher Neal C | Buy | 1,315,339 | 1.47 | 1,938,809 |
| 2024-04-11 | Riggs Josh (CEO and President) | Buy | 3,390 | 2.95 | 10,000 |
| 2024-04-11 | Arno Andrew | Buy | 33,898 | 2.95 | 99,999 |
| 2024-04-11 | Bradsher Neal C | Buy | 2,420,000 | 1.46 | 3,528,360 |
| 2023-06-14 | Kingsley Alfred D | Buy | 30,000 | .21 | 6,450 |
| 2023-04-05 | Kamen Efrem (10% Owner) | Buy | 663,000 | .30 | 200,226 |
| 2023-04-03 | Bradsher Neal C | Buy | 26,827,638 | .15 | 4,050,973 |
| 2022-12-23 | Gutfreund John Peter | Buy | 75,000 | .33 | 24,750 |
| 2022-12-23 | Arno Andrew | Buy | 250,000 | .35 | 88,000 |
| 2022-12-22 | Kingsley Alfred D | Buy | 25,000 | .28 | 7,124 |
| 2022-12-01 | Andrews Ronald Asbury (Former CEO) | Option Ex | 250,000 | .00 | 0 |
| 2022-08-17 | Last Andrew J. | Buy | 20,000 | .87 | 17,400 |
| 2022-08-17 | Arno Andrew | Buy | 15,000 | .90 | 13,500 |
| 2022-08-16 | Carter Jennifer L. | Buy | 10,500 | .95 | 9,975 |
| 2022-08-16 | Griffith Melinda | Buy | 10,000 | 1.00 | 10,000 |
| 2022-08-16 | Arno Andrew | Buy | 115,523 | .97 | 112,057 |
| 2022-08-16 | Andrews Ronald Asbury (President & CEO) | Buy | 40,000 | .96 | 38,400 |
| 2022-08-15 | Gutfreund John Peter | Buy | 25,000 | .93 | 23,250 |
| 2022-08-15 | Arno Andrew | Buy | 34,477 | .93 | 32,063 |
| 2022-08-15 | Kingsley Alfred D | Buy | 10,000 | .97 | 9,700 |
| 2022-06-24 | Carter Jennifer L. | Option Ex | 10,000 | .00 | 0 |
| 2022-06-24 | Kamen Efrem (10% Owner) | Sale | 99,386 | 1.04 | 103,262 |
| 2022-06-24 | Griffith Melinda | Option Ex | 10,000 | .00 | 0 |
| 2022-06-24 | Last Andrew J. | Option Ex | 10,000 | .00 | 0 |
| 2022-06-24 | Arno Andrew | Option Ex | 10,000 | .00 | 0 |
| 2022-06-24 | Redmond Cavan M. | Option Ex | 10,000 | .00 | 0 |
| 2022-06-24 | Kingsley Alfred D | Option Ex | 10,000 | .00 | 0 |
| 2022-05-18 | Yu Li (VP Cntrllr/Prncpl Acctng Offcr) | Sale | 8,128 | 1.14 | 9,265 |
| 2022-05-18 | Yu Li (VP Cntrllr/Prncpl Acctng Offcr) | Option Ex | 25,000 | .00 | 0 |
| 2022-04-14 | Kamen Efrem | Buy | 5,931,707 | 1.29 | 7,640,038 |
| 2022-04-14 | Broadwood Capital Inc | Buy | 6,003,752 | .67 | 3,998,498 |
| 2022-03-25 | Ross Douglas T. (Chief Scientific Officer) | Buy | 15,000 | 1.40 | 21,000 |
| 2022-03-17 | Paulsen Gisela (Chief Operating Officer) | Buy | 16,500 | 1.20 | 19,767 |
| 2022-03-16 | Redmond Cavan M. | Buy | 40,000 | 1.19 | 47,560 |
| 2022-03-16 | Andrews Ronald Asbury (Chief Executive Officer) | Buy | 50,000 | 1.28 | 64,149 |
| 2022-03-15 | Levine Mitchell S (Chief Financial Officer) | Buy | 25,000 | 1.17 | 29,149 |
| 2021-07-01 | Andrews Ronald Asbury (Chief Executive Officer) | Option Ex | 65,000 | .00 | 0 |
| 2021-04-28 | Levine Mitchell S (Chief Financial Officer) | Option Ex | 20,000 | .00 | 0 |
| 2021-03-19 | Andrews Ronald Asbury (Chief Executive Officer) | Buy | 11,000 | 4.79 | 52,701 |
| 2021-02-05 | Bradsher Neal C | Buy | 600,000 | 2.25 | 1,350,000 |
| 2021-01-20 | Bradsher Neal C | Buy | 1,460,280 | 1.71 | 2,499,999 |
| 2020-12-28 | Kingsley Alfred D | Option Ex | 65,271 | 1.34 | 87,463 |
| 2020-12-23 | Kingsley Alfred D | Sale | 900 | 2.55 | 2,295 |
| 2020-12-23 | Kingsley Alfred D | Option Ex | 1,237 | 1.34 | 1,657 |
| 2020-12-22 | Kingsley Alfred D | Sale | 7,652 | .00 | 0 |
| 2020-12-22 | Kingsley Alfred D | Option Ex | 10,516 | 1.34 | 14,091 |
| 2020-12-21 | Kingsley Alfred D | Sale | 35,148 | 1.27 | 44,637 |
| 2020-12-21 | Kingsley Alfred D | Option Ex | 47,976 | 1.34 | 64,287 |
| 2020-08-03 | Kalajian Tony T (Sr.VP/Chief Accounting Officer) | Buy | 5,000 | 1.31 | 6,535 |
| 2020-08-03 | Parker Albert P (Chief Operating Officer) | Buy | 5,000 | 1.33 | 6,650 |
| 2020-08-03 | Levine Mitchell S (Chief Financial Officer) | Buy | 10,000 | 1.32 | 13,200 |
| 2020-08-03 | Andrews Ronald Asbury (Chief Executive Officer) | Buy | 40,000 | 1.35 | 53,880 |
| 2020-04-24 | Bradsher Neal C | Buy | 1,050,000 | 1.14 | 1,191,750 |
| 2020-03-31 | Andrews Ronald Asbury (CEO and President) | Buy | 18,000 | 2,372.00 | 42,696,000 |
| 2020-03-30 | Andrews Ronald Asbury (CEO and President) | Buy | 27,216 | 2.26 | 61,453 |
| 2020-03-14 | Levine Mitchell S (Chief Financial Officer) | Option Ex | 20,000 | .00 | 0 |
| 2020-01-02 | Bradsher Neal C | Buy | 1,391,466 | 1.08 | 1,500,000 |
| 2020-01-02 | Lineage Cell Therapeutics, Inc. | Sale | 2,383,090 | 2.16 | 5,137,942 |
| 2019-11-13 | Bradsher Neal C | Buy | 1,176,471 | .85 | 1,000,000 |
| 2019-09-17 | Arno Andrew (Director) | Buy | 50,000 | 2.16 | 108,149 |
| 2019-09-13 | Kalajian Tony T (SVP-Chief Accounting Officer) | Buy | 10,000 | 1.98 | 19,800 |
| 2019-09-12 | Levine Mitchell S (Chief Financial Officer) | Buy | 10,000 | 2.01 | 20,059 |
| 2019-09-11 | Bradsher Neal C | Buy | 2,000,000 | .83 | 1,660,000 |
| 2019-09-11 | Lineage Cell Therapeutics, Inc. | Sale | 4,000,000 | 1.66 | 6,640,000 |
| 2019-07-05 | Biotime Inc (10% Owner) | Sale | 2,250,000 | 2.00 | 4,500,000 |
| 2019-07-02 | Bradsher Neal C | Buy | 1,000,000 | 2.00 | 2,000,000 |
| 2019-02-08 | Bradsher Neal C | Buy | 533,333 | 3.75 | 1,999,998 |
| 2018-07-26 | Hesterberg Lyndal K. (Sr VP, Research & Development) | Buy | 874 | .00 | 0 |
| 2018-07-26 | Annett William (President and CEO) | Buy | 3,500 | .00 | 0 |
| 2018-07-26 | Last Andrew J. | Buy | 6,993 | .00 | 0 |
| 2018-07-26 | Arno Andrew | Buy | 52,447 | .00 | 0 |
| 2018-07-26 | Redmond Cavan M. | Buy | 52,447 | .00 | 0 |
| 2018-07-26 | Levine Mitchell S (Chief Financial Officer) | Buy | 3,495 | .00 | 0 |
| 2018-07-26 | Andrews Ronald Asbury | Buy | 17,482 | .00 | 0 |
| 2018-03-28 | Bradsher Neal C | Buy | 3,968,254 | 1.26 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of OCX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Oncocyte Corp (symbol OCX, CIK number 1642380) see the Securities and Exchange Commission (SEC) website.